Zhu, P., Du, X. L., Lu, G., & Zhu, J. (2017). Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. Oncotarget.
Citação norma ChicagoZhu, Ping, Xianglin L. Du, Guangrong Lu, e Jay-Jiguang Zhu. "Survival Benefit of Glioblastoma Patients After FDA Approval of Temozolomide Concomitant With Radiation and Bevacizumab: A Population-based Study." Oncotarget 2017.
Citação norma MLAZhu, Ping, Xianglin L. Du, Guangrong Lu, e Jay-Jiguang Zhu. "Survival Benefit of Glioblastoma Patients After FDA Approval of Temozolomide Concomitant With Radiation and Bevacizumab: A Population-based Study." Oncotarget 2017.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.